IMCR - Company ID 0001671927
Immunocore Holdings plc trades as IMCR and has a market capitalization of $1.68 B, making it the #2282 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $400.02M, up 29.0% from the prior year and net income of -$35.51M. This page tracks Immunocore Holdings plc through 263 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 4 fiscal years Immunocore Holdings plc's revenue grew from $36.48M to $400.02M, a compound annual growth rate of 82.0%. Net profit margin expanded from -493.4% to -8.9% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-22 |
| Insider sale notice | 144 | 2026-05-21 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| Employee stock plan | S-8 | 2026-05-08 |
| Quarterly report | 10-Q | 2026-05-06 |
| Major company event | 8-K | 2026-05-06 |
| Annual report to shareholders | ARS | 2026-04-16 |
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma :: Immunocore Holdings plc (IMCR)
Immunocore reports first quarter financial results and provides a business update :: Immunocore Holdings plc (IMCR)
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference :: Immunocore Holdings plc (IMCR)
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting :: Immunocore Holdings plc (IMCR)
The largest companies sharing Immunocore Holdings plc's SEC industry classification (biological products, (no diagnostic substances)).
Immunocore Holdings plc (IMCR) has a market capitalization of $1.68 B as of 2026-07-09, ranking #2282 among US-listed companies.
Immunocore Holdings plc reported revenue of $400.02M for fiscal year 2025, an increase of 29.0% year over year.
In its latest fiscal year Immunocore Holdings plc reported a net loss of $35.51M.